3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
Specimen Handling
4
Gemcitabine
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Oxaliplatin
3
Fluorouracil
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
130-nm albumin-bound paclitaxel
3
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
IDRX-42
2
Folfox protocol
2
Endoscopy, Digestive System
2
Biopsy
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
s-formylglutathione hydrolase
1
repotrectinib
1
regorafenib
1
plecanatide
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
abelacimab
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled